Musings from The Power List: Daniel Vitt
By Daniel Vitt
August 20, 2026
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
6 min read
False
Advertisement
Drug Discovery
Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?
August 12, 2026
NurExone CEO Lior Shaltiel discusses the company’s exosome-based approach to nerve regeneration, the manufacturing hurdles facing the field, and what it will take to bring nanotechnology therapeutics to patients
11 min read
Musings from The Power List: Ann Cleves
By Ann Cleeves
August 11, 2026
Ann Cleves on why the future of small-molecule drug discovery lies beyond the rule of five
3 min read
This Week’s CGT News: Gene-Editing Trial Death Raises Concerns
August 3, 2026
A previously undisclosed death in China raises questions about gene-editing oversight, deramiocel meets its Phase 3 Duchenne endpoint, and researchers identify a source of CAR NK dysfunction
4 min read
The Confidentiality Barrier to AI-Enabled Drug Development
By Timothy Pas, Laure Descamps
July 27, 2026
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
3 min read
Inside the Rise of circRNA
July 9, 2026
Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality
11 min read
Are Researchers Learning to Trust AI?
July 8, 2026
Elsevier’s Mirit Eldor explores the gap between AI adoption and AI confidence, drawing on findings from the Researcher of the Future report
7 min read
AI Framework Helps Identify New CAR T Target
July 6, 2026
A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models
2 min read
CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis
June 30, 2026
A single infusion of engineered T cells degraded soluble TNF and produced durable disease control in mice
2 min read
Reformulating the Future of Small Molecules
June 30, 2026
A special collection of recent stories exploring oral dose innovation, API stability, nitrosamine testing, and the evolving science of small molecule medicines
1 min read
